Qiming Venture Partners and Quan Capital led a $120m Series B round in OriCell Therapeutics.

Venture capital firms Qiming Venture Partners and Quan Capital led a $120m Series B round in OriCell Therapeutics, a biotechnology company. "We are grateful to our new and existing investors for their continued support in OriCell. We have achieved a number of significant milestones in terms of clinical development of our CAR-T and partnered bispecific antibody programs, as well as continued to strengthen our senior management team. We look forward to delivering more innovative discoveries and clinical milestones in the next three years. In today's open, inclusive, and dynamic innovative pharmaceutical ecosystem in China, we endeavor to become a world leading cell therapy company with a broad vision that can integrate seamlessly into the global market," Helen Yang, OriCell Chairman and CEO.